Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- Acronyms RAMP
- 01 Feb 2017 Status changed from recruiting to discontinued.
- 16 Mar 2016 Planned number of patients changed from 90 to 64 as reported by ClinicalTrials.gov record.
- 19 May 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.